Peer reviewed articles on which we base and support our practice.

Authored or coauthored by Dr. Rader

Clinical experience using appetite suppressants and SSRIsRader, W. Allen, Steelman, Westman, 2008 OK Journal article 101:8 180-181
Overweight and Obesity Evaluation and ManagementDr W. Allen Rader Chairperson OOEM task force ASBP

Other articles on which we base our practice

Obesity AlgorithmSeger JC, Horn DB, Westman EC, Primack C, Schmidt SL, Ravasia D, McCarthy W, Ferguson U, Sabowitz BN, Scinta W, Bays HE. Obesity Algorithm, presented by the American Society of Bariatric Physicians, 2014-2015.
Weight Loss; Slow and steady does not win the racewww.the -endocrinology Vol 2 December 2014
Read more
Committee Opinion American College of Obstetrics and GynecologyNumber 549 Jan 2013
Intentional Weight Loss and all-cause mortality: a meta analysis of clinical trialsPLoS one 2015 Mar 20;10(3) :e0121993.
Systematic review: an evaluation of major commercial weight loss programs in the USAnn Intern Med 2005 Jan; 142 (1) 56-66
Tailored Implementation of Evidence based practice for patients with chronic diseasePLoS one 2014 ;9(7); e101981
Effectiveness-Based Guidelines for the prevention of Cardiovascular Disease in Women 2011 update A guideline from the American Heart AssociationCirculation. 2011 123; 1243-1262
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. U.S. Department of Health and Human Services,National Institutes of Health. NIH Publication No. 98-4083, (September 1998).
Read more
Drug treatment of obesity.Weintraub M, Bray GA. Med Clin North Am. 1989; 73:237-249.
Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.Bays H, Dujovne CA. Curr Atherosclerosis Rep 2006;8(2):144-56.
Nurses health study reference of states and obesity
BHRSS survey
Drug abuse warning report (DAWN).U.S. Department of Health and Human Services. (2006).
JAMA January 8,2003 Vol 289 No. 2Pathophysiology of obesity
Adiposopathy: How do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?.Bays H, Blonde L, Rosenson R. Expert Review of Cardiovascular Therapy 2006;4(6):871-95
Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular risk.Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM Current Treatment Options in Cardiovascular Medicine 2007;9:259-71.
Long-term pharmacotherapy in the management of obesity.National Task Force on the Prevention and Treatment of Obesity. JAMA 1996;276(23):1907-15.
Use and abuse of appetite-suppressant drugs in the treatment of obesity.Bray GA. Ann Intern Med 1993;119(7_Part_2):707-13.
The long-term management of obesity with continuing pharmacotherapy.Frank A. Obes Res 2004;12(11):1821-7.
NIH evidence report NO 98-4083.Sept 1998.National Institute of Health Chapter 4 treatment guidelines, page 86.
Off-label prescribing among office-based physicians.Radley DC, Finkelstein SN, Stafford RS. Arch Intern Med 2006;166(9):1021-6.
Beneficial health effects of modest weight loss.Goldstein, David J. (1992): Int J of Obesity. 16:397-415
Drug Treatment of Obesity. Weintraub, Michael Bray, George A. (1989) Medical Clinics of North America. 73:237-249.
Nutrition Today, Vol.19. #4, July/1984, Pg. 22; also see, Am J Clin Nutri. 39:152Making Changes in Anorectic Medications
Long-term weight loss: the effect of pharmacologic agents.Goldstein, D.J. Potvin, J.H. (1994) Am J Clin Nutr. 60(5):647-657
Drug therapy for the obese patients.Bray, G.A. (1976); In “The obese Patient,: pp.353-410. Philadelphia: W.B. Saunders
Long term weight control: The National Heart, Lung and Blood Institute funded multimodal intervention.Weintraub M, et al (1992); Clin Pharmacol Ther. 51(5):581-646.
Review of amphetamine-like drugs by the Food and Drug Administration: Clinical data and value judgements, in Bray, GA (ed): Obesity in perspective.Scoville, Barrett (1975); DHEW Publ No. 9. (NIH) 75-708, Bethesda, MD National Institutes of Health: 441-443.
ASBP Poster Presentation Hendricks
Guidelines for the Approval and Use of Drugs to Treat Obesity.NAASO Task Force (1995): Obes Res. 3(5): 473-478
Prescription of Drugs: The AMA reiterates that it is appropriate and legal for physicians to prescribe approved drugs for uses not included in their official labeling when they can be supported as rational and accepted medical practice.AMA Policy Compendium, 1995, 120.992.
An Observational Study – The North American Association for the Study of Obesity 9:652-653: Long-Term Medication Use and Weight Loss Maintenance:Womble, LG; Wadden, T.A.; Berkowitz, RI; Sarwer, DB; Rotherman, RA (2001);
Shape Up America and The American Obesity Association; Guidance for the Treatment of Adult Obesity, November, 1996.
Bray G. Evaluation of total and regional body composition.In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York-Basel: Marcel Dekker, Inc., 1998, 831-54.
Stimulant medications cause no increase in Cardiovascular mortalityJAMA 2011;306(24):2673-2683 Habel
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.Rothman RB, Baumann MH. American Journal of Therapeutics 2009, 16 (4), 354-364 310.1097/MJT.1090b1013e31817fde31895.
Treatment of obesity with Combination Pharmacotherapy. 10.1097/MJT.1090b1013e31818e31830da.Rothman RB. American Journal of Therapeutics 2009, e-publish ahead of print,
How physician obesity specialists use drugs to treat obesity.Hendricks EJ,Rothman RB, Greenway FL. Obesity 2009, 17 (9), 1730-1735.
AAFP May 2009 position statement on routine EKGs for patients on stimulant medications
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994):ollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb; 87(2): 486-8.
Fat cell adrenergic receptors and the control of white and brown fat cell function.Lafontan M, Berlan M. J Lipid Res 1993; 34:1057-1091
Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance.Astrup A, Rossner S Obes Rev 2000;1:17-19
The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race?Nackers LM, Ross KM, Perri MG.Int J Behav Med2010;17:161-167
Clinical correlates of short- and long-term weight loss.Wadden TA1, Foster GD, Wang J, Pierson RN, Yang MU, Moreland K, Stunkard AJ, VanItallie TBAm J Clin Nutr. 1992 Jul;56(1 Suppl):271S-274S.
Swedish Observation study of Weight loss in surgical Patients4 Sjostrom L NEJM 2007 357 741-52
The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot StudyDavid Tendler · Sauyu Lin · William S. Yancy Jr. ·John Mavropoulos · Pam Sylvestre · Don C. Rockey ·Eric C.Westman Dig Dis Sci (2007) 52:589–593 DOI 10.1007/s10620-006-9433-5
Patient Centered Outcomes researchJAMA , September 21, 2011- Vol 36,No11 pg. 1254
Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-MorbiditiesResults of EQUIP and CONQUER Phase 3 Studies Exceed FDA Benchmarks for Obesity Treatments, Demonstrate Positive Safety ProfileVIVUS Announces Positive Results From Two Phase 3 Studies; (Vivus press release Sept 9 2009) (phentermine plus topiramate)
(Behavioral modification and Locaserin Second Study for Obesity Management) trialBLOSSOM Press release Arena Phamaceuticals Sept 18 2009 (Locaserin is a 5HT2C agonist)
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialGreenway Lancet Vol 36 pgs 595 605